License is based on option for preclinical-stage long-acting anti-obesity protein drug candidate. Israeli firm Prolor Biotech has negotiated an exclusive license to a technology known as Reversible ...
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK), today announced that the company will present new data on its long-acting clotting Factor VIIa-CTP (MOD-5014) at the International Society on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results